Erasca Announces Positive Preliminary Phase 1 Dose Escalation Data for Potentially Best-in-Class Pan-RAS Molecular Glue ERAS-0015 in KRAS-Mutant Solid Tumors
Go back to Erasca Announces Positive Preliminary Phase 1 Dose Escalation Data for Potentially Best-in-Class Pan-RAS Molecular Glue ERAS-0015 in KRAS-Mutant Solid Tumors| (NASDAQ: ERAS) | Delayed: 19.51 +0.13 (0.67%) | |||||
|---|---|---|---|---|---|---|
| Previous Close | $19.38 | 52 Week High | $ | |||
| Open | $18.94 | 52 Week Low | $ | |||
| Day High | $19.81 | P/E | N/A | |||
| Day Low | $18.86 | EPS | $ | |||
| Volume | 3,076,576 | |||||
